发布求助
文献互助 智能选刊 最新文献

Nature Reviews. Drug Discovery最新文献

筛选
英文 中文
Identifying antimicrobials in the human microbiome 识别人类微生物群中的抗菌素
IF 122.7 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2024-09-27 DOI: 10.1038/d41573-024-00157-6
Sarah Crunkhorn
{"title":"Identifying antimicrobials in the human microbiome","authors":"Sarah Crunkhorn","doi":"10.1038/d41573-024-00157-6","DOIUrl":"10.1038/d41573-024-00157-6","url":null,"abstract":"","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"23 11","pages":"816-816"},"PeriodicalIF":122.7,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142321969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting the kynurenine pathway 靶向犬尿氨酸途径
IF 122.7 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2024-09-27 DOI: 10.1038/d41573-024-00160-x
Sarah Crunkhorn
{"title":"Targeting the kynurenine pathway","authors":"Sarah Crunkhorn","doi":"10.1038/d41573-024-00160-x","DOIUrl":"10.1038/d41573-024-00160-x","url":null,"abstract":"","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"23 11","pages":"816-816"},"PeriodicalIF":122.7,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142321958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
FDA approves first schizophrenia drug with new mechanism of action since 1950s 美国食品和药物管理局批准自 20 世纪 50 年代以来首款具有新作用机制的精神分裂症药物
IF 122.7 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2024-09-26 DOI: 10.1038/d41573-024-00155-8
Katie Kingwell
{"title":"FDA approves first schizophrenia drug with new mechanism of action since 1950s","authors":"Katie Kingwell","doi":"10.1038/d41573-024-00155-8","DOIUrl":"10.1038/d41573-024-00155-8","url":null,"abstract":"","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"23 11","pages":"803-803"},"PeriodicalIF":122.7,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142321936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A tale of two ecosystems: the biopharma landscape in China and India 两个生态系统的故事：中国和印度的生物制药格局
IF 122.7 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2024-09-25 DOI: 10.1038/d41573-024-00152-x
Ajay Gautam
{"title":"A tale of two ecosystems: the biopharma landscape in China and India","authors":"Ajay Gautam","doi":"10.1038/d41573-024-00152-x","DOIUrl":"10.1038/d41573-024-00152-x","url":null,"abstract":"","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"23 11","pages":"807-807"},"PeriodicalIF":122.7,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142317057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting neurofibrosis reverses metabolic dysfunction 以神经纤维化为目标可逆转代谢功能障碍
IF 122.7 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2024-09-25 DOI: 10.1038/d41573-024-00156-7
Sarah Crunkhorn
{"title":"Targeting neurofibrosis reverses metabolic dysfunction","authors":"Sarah Crunkhorn","doi":"10.1038/d41573-024-00156-7","DOIUrl":"10.1038/d41573-024-00156-7","url":null,"abstract":"","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"23 11","pages":"813-813"},"PeriodicalIF":122.7,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142317056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Agonist antibody lowers blood pressure 激动剂抗体可降低血压
IF 122.7 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2024-09-23 DOI: 10.1038/d41573-024-00151-y
Alex Eccleston
{"title":"Agonist antibody lowers blood pressure","authors":"Alex Eccleston","doi":"10.1038/d41573-024-00151-y","DOIUrl":"10.1038/d41573-024-00151-y","url":null,"abstract":"","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"23 11","pages":"815-815"},"PeriodicalIF":122.7,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142276784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The AMR Accelerator: from individual organizations to efficient antibiotic development partnerships AMR 加速器：从单个组织到高效抗生素开发伙伴关系
IF 122.7 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2024-09-23 DOI: 10.1038/d41573-024-00138-9
Josepine Fernow,  Marie Olliver,  William Couet,  Sophie Lagrange,  Meindert H. Lamers,  Ole F. Olesen,  Kristina Orrling,  Michel Pieren,  Derek J. Sloan,  Juan José Vaquero,  Timothy J. Miles,  Anders Karlén
{"title":"The AMR Accelerator: from individual organizations to efficient antibiotic development partnerships","authors":"Josepine Fernow, \u0000 Marie Olliver, \u0000 William Couet, \u0000 Sophie Lagrange, \u0000 Meindert H. Lamers, \u0000 Ole F. Olesen, \u0000 Kristina Orrling, \u0000 Michel Pieren, \u0000 Derek J. Sloan, \u0000 Juan José Vaquero, \u0000 Timothy J. Miles, \u0000 Anders Karlén","doi":"10.1038/d41573-024-00138-9","DOIUrl":"10.1038/d41573-024-00138-9","url":null,"abstract":"The AMR Accelerator is an Innovative Medicines Initiative programme integrating nine projects with the shared goal of progressing the development of new antibiotics and building antimicrobial resistance research capability. Five years in, we reflect on the programme’s value, results and key challenge: ensuring the sustainability of assets, infrastructures and expertise. The AMR Accelerator is an Innovative Medicines Initiative programme integrating nine projects with the shared goal of progressing the development of new antibiotics and building antimicrobial resistance research capability. Five years in, we reflect on the programme’s value, results and key challenge: ensuring the sustainability of assets, infrastructures and expertise.","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"24 1","pages":"1-2"},"PeriodicalIF":122.7,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142276788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Publisher Correction: Strategies to therapeutically modulate cytokine action 出版商更正：调节细胞因子作用的治疗策略。
IF 122.7 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2024-09-20 DOI: 10.1038/s41573-024-01055-7
Warren J. Leonard, Jian-Xin Lin
{"title":"Publisher Correction: Strategies to therapeutically modulate cytokine action","authors":"Warren J. Leonard, Jian-Xin Lin","doi":"10.1038/s41573-024-01055-7","DOIUrl":"10.1038/s41573-024-01055-7","url":null,"abstract":"","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"23 11","pages":"880-880"},"PeriodicalIF":122.7,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41573-024-01055-7.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142275171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In vivo CAR T cells move into clinical trials 体内 CAR T 细胞进入临床试验阶段
IF 122.7 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2024-09-16 DOI: 10.1038/d41573-024-00150-z
Asher Mullard
{"title":"In vivo CAR T cells move into clinical trials","authors":"Asher Mullard","doi":"10.1038/d41573-024-00150-z","DOIUrl":"10.1038/d41573-024-00150-z","url":null,"abstract":"Drug developers want to reprogramme immune cells directly in the body, opening up new gene therapy frontiers in cancer and autoimmunity. Drug developers want to reprogramme immune cells directly in the body, opening up new gene therapy frontiers in cancer and autoimmunity.","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"23 10","pages":"727-730"},"PeriodicalIF":122.7,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142235218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Creating an AI-first drug discovery engine 创建人工智能药物发现引擎
IF 122.7 1区 医学
Nature Reviews. Drug Discovery Pub Date : 2024-09-13 DOI: 10.1038/d41573-024-00149-6
Asher Mullard
{"title":"Creating an AI-first drug discovery engine","authors":"Asher Mullard","doi":"10.1038/d41573-024-00149-6","DOIUrl":"10.1038/d41573-024-00149-6","url":null,"abstract":"Najat Khan — Chief R&D Officer and Chief Commercial Officer at Recursion — discusses the proposed merger of Recursion and Exscientia. Najat Khan — Chief R&D Officer and Chief Commercial Officer at Recursion — discusses the proposed merger of Recursion and Exscientia.","PeriodicalId":19068,"journal":{"name":"Nature Reviews. Drug Discovery","volume":"23 10","pages":"734-735"},"PeriodicalIF":122.7,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142174922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信